The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
Abstract
In view of non-specific toxicity of most chemotherapeutic agents against normal cells, the development of targeted chemotherapy is warranted. Efficient targeting of chemotherapeutic drugs to the cancerous area could be of great benefit for patients with advanced or metastatic tumors. Targeted cytotoxic peptide conjugates are hybrid molecules composed of a peptide carrier which binds to receptors on tumors and a cytotoxic moiety. New cytotoxic analogs of LHRH, AN-152 in which doxorubicin (DOX) is linked to [d-Lys(6)]LHRH, and AN-207 which consists of 2-pyrrolino-DOX (AN-201) coupled to the same carrier, show high-affinity binding and are much less toxic and more effective in vivo than their respective radicals in inhibiting tumor growth in LHRH receptor-positive models of human ovarian, mammary, or prostatic cancer. These results suggest that targeted cytotoxic LHRH analogs such as AN-207 could be considered for treatment of these cancers. The presence of receptors for bombesin-like peptides on a wide variety of tumors prompted us to use some of our bombesin/gastrin-releasing peptide antagonists as carrier molecules. Cytotoxic bombesin analogs, such as AN-215 containing AN-201, might find application in the treatment of small cell lung carcinoma (SCLC), and colorectal, gastric, pancreatic, mammary, and prostatic cancers. Since somatostatin receptors are found in various human neoplasms and the receptor subtypes to which octapeptide analogs bind with high affinity have been identified, we synthesized several cytotoxic somatostatin analogs including AN-162 and AN-238 containing DOX and 2-pyrrolino-DOX respectively, linked to octapeptide RC-121. Cytotoxic somatostatin analog AN-238 efficaciously inhibits growth of human breast or prostate cancers expressing somatostatin receptors-2 and -5 and can be used for receptor-targeted chemotherapy. Cytotoxic somatostatin analogs might also find applications for the therapy of human pancreatic, colorectal, and gastric cancer as well as brain tumors and non-SCLC. Cytotoxic compounds linked to analogs of hormonal peptides like LHRH, bombesin, and somatostatin that can be targeted to certain tumors possessing receptors for those peptides could be an important addition to oncological armamentarium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
Cuttitta, F., Carney, D. N., Mulshine, J., Moody, T. W., Fedorko, J., Fischler, A., & Minna, J. D. (1985) · Nature · doi:10.1038/316823a0 · Cited by 1,349
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., & Pless, J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90087-x · Cited by 1,331
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
LAMBERTS, S. W. J., KRENNING, E. P., & REUBI, J.-C. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-4-450 · Cited by 805
Molecular Biology of Somatostatin Receptors*
REISINE, T., & BELL, G. I. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-427 · Cited by 618
The Anticancer Agent Adriamycin Can Be Actively Cytotoxic Without Entering Cells
Triton, T. R., & Yee, G. (1982) · Science · doi:10.1126/science.7089561 · Cited by 571
KARTEN, M. J., & RIVIER, J. E. (1986) · Endocrine Reviews · doi:10.1210/edrv-7-1-44 · Cited by 560
The somatostatin receptor family
Patel, Y. C., Greenwood, M. T., Panetta, R., Demchyshyn, L., Niznik, H., & Srikant, C. B. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02082-t · Cited by 367
The Collected Papers of Paul Ehrlich
(2013) · Elsevier eBooks · doi:10.1016/c2013-0-01635-0 · Cited by 365
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E., Herrmann, R., & Maecke, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78355-0 · Cited by 335
Buscail, L., Delesque, N., Estève, J. P., Saint-Laurent, N., Prats, H., Clerc, P., Robberecht, P., Bell, G. I., Liebow, C., & Schally, A. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2315 · Cited by 327
Self-citationMolecular biology of somatostatin receptors
Bell, G. I., & Reisine, T. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90050-v · Cited by 319
Recombinant Toxins for Cancer Treatment
Pastan, I., & FitzGerald, D. (1991) · Science · doi:10.1126/science.1683495 · Cited by 299
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
Miller, W. R., Scott, W. N., Morris, R. A., Fraser, H. M., & Sharpe, R. M. (1985) · Nature · doi:10.1038/313231a0 · Cited by 293
Shen, W.-C., & Ryser, H. J.-P. (1981) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(81)91644-2 · Cited by 277
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers
Emons, G., & Schally, A. V. (1994) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a138714 · Cited by 244
Self-citationTrouet, A., Masquelier, M., Baurain, R., & Deprez-De Campeneere, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.2.626 · Cited by 233
Somatostatin analogs in the diagnosis and treatment of cancer
Lamberts, S. W. J., de Herder, W. W., & Hofland, L. J. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00667-7 · Cited by 217
EIDNE, K. A., FLANAGAN, C. A., HARRIS, N. S., & MILLAR, R. P. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-3-425 · Cited by 216
Emons, G. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.6.1458 · Cited by 204
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
Buscail, L., Saint‐Laurent, N., Chastre, E., Vaillant, J., Gespach, C. P., Capellá, G., Kalthoff, H., Lluı́s, F., Vaysse, N., & Susini, C. (1996) · PubMed · Cited by 201
Fekete, M., Wittliff, J. L., & Schally, A. V. (1989) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860030302 · Cited by 200
Self-citationLimonta, P., Dondi, D., Moretti, R. M., Maggi, R., & Motta, M. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.1.207 · Cited by 152
Qayum, A., Gullick, W. J., Clayton, R., Sikora, K., & Waxman, J. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.236 · Cited by 150
Nagy, A., Schally, A. V., Halmos, G., Armatis, P. E., Cai, R., CSERNUS, V. J., Kovács, M., Koppán, M., Szepesházi, K., & Kahán, Z. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1794 · Cited by 146
Self-citationExpression and Signal Transduction Pathways of Gonadotropin-Releasing Hormone Receptors
Stojilković, S. S., & Catt, K. J. (1995) · Elsevier eBooks · doi:10.1016/b978-0-12-571150-0.50012-3 · Cited by 141
Kakar, S. S., Grizzle, W. E., & Neill, J. D. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90196-1 · Cited by 139
Nagalla, S. R., Barry, B. J., Creswick, K. E., Eden, P., Taylor, J. T., & Spindel, E. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.6205 · Cited by 138
Molecular biology of somatostatin receptor subtypes
Patel, Y., Greenwood, M. T., Panetta, R., Hukovic, N., Grigorakis, S., Robertson, L.-A., & Srikant, C. B. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90076-1 · Cited by 109
Srkalović, G., Wittliff, J. L., & Schally, A. V. (1990) · PubMed · Cited by 107
Self-citationIrmer, G., Bürger, C., Müller, R., Ortmann, O., Peter, U., Kakar, S. S., Neill, J. D., Schulz, K. ‐., & Emons, G. (1995) · PubMed · Cited by 106
Growth-Inhibitory Actions of Analogues of Luteinizing Hormone Releasing Hormone on Tumor Cells
Emons, G., Ortmann, O., Schulz, K.-D., et al. (1997) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(97)00155-0 · Cited by 106
Bombesin-Like Peptides: Of Ligands and Receptors
Spindel, E. R., Giladi, E., Segerson, T. P., & Nagalla, S. R. (1993) · Elsevier eBooks · doi:10.1016/b978-0-12-571148-7.50017-8 · Cited by 102
Molecular Biology of Somatostatin Receptors
Bell, G. I., Yasuda, K., Kong, H., Law, S. F., Raynor, K., & Reisine, T. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514733.ch5 · Cited by 76
Radulovic, S. S., Cai, R., Serfözö, P. D., et al. (1991) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1991.tb01545.x · Cited by 75
Miyazaki, M., Nagy, A., Schally, A. V., Lamharzi, N., Halmos, G. B., Szepesházi, K., Groot, K., & Armatis, P. E. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1803 · Cited by 70
Self-citationPotent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.
Cai, R. Z., Reile, H., Armatis, P. E., & Schally, A. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12664 · Cited by 52
Self-citationHalmos, G., Nagy, A., Lamharzi, N., et al. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00316-4 · Cited by 49
Self-citationLamharzi, N., Halmos, G. B., Jungwirth, A., & Schally, A. V. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.3.429 · Cited by 42
Self-citationAnalysis of somatostatin receptor subtype mRNA expression in human breast cancer
Evans, A., Crook, T., Laws, S., Gough, A. C., Royle, G. T., & Primrose, J. M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.143 · Cited by 39
Schally, A. V., & Comaru‐Schally, A. M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00056-2 · Cited by 33
Self-citationMiyazaki, M., Schally, A. V., Nagy, A., Lamharzi, N., Halmos, G., Szepesházi, K., & Armatis, P. E. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70600-9 · Cited by 30
Self-citationYano, T., Korkut, E., Pinski, J., Szepesházi, K., Milovanović, S. R., Groot, K., Clarke, R. C., Comaru‐Schally, A. M., & Schally, A. V. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01811962 · Cited by 30
Self-citationLH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro
Szoke, B. G., Horvath, J. E., Halmos, G., et al. (1994) · Peptides · doi:10.1016/0196-9781(94)90024-8 · Cited by 22
Cited by
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
Jensen, R. T., Battey, J. F., Spindel, E. R., & Benya, R. V. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07108 · Cited by 536
Metadata
- Authors
- Schally, A., & Nagy, A.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-07-01
- Volume
- 141
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2128302079
- Cited by
- 271
- References
- 45
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.